01 42 54 60 64 | contact@welcomeurope.com

Covid-19: first potential vaccine funded by the EU’s emergency aid instrument

publié le 20 August 2020

A first agreement between the European Commission and the pharmaceutical company AstraZeneca was concluded on the 14th of August. This agreement provides for the purchase of a potential vaccine against COVID-19 and for donations to low- and middle-income countries or retransfers to other European countries.

The agreement between the Commission and AstraZeneca was entered into on behalf of the Member States of the European Union and covers the purchase of 300 million doses of vaccine with an option to purchase a further 100 million doses. In parallel, the Commission is continuing its negotiations with other manufacturers and hopes to conclude other similar agreements.
Like the this one, the next agreements will also be financed by the EU’s emergency aid instrument, which allocates funds for the creation of a portfolio of potential vaccines.

Eurofunding gathers more than 300 European grant programs updated and linked to weekly alerts on calls for projects. Subscribe for free and don't miss any more opportunities.

Subscribe to Eurofunding

Similar news

2020-03-13 10:02:46

12 million euro Danish scheme approved by the European Commission in response to the cancellations of large public events due to COVID-19

Lire l'aticle

2020-09-17 15:55:34

Commission approval of Italian State aid for large companies affected by Covid19

Lire l'aticle